OncoMatch/Clinical Trials/NCT05929885
Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients
Is NCT05929885 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Low Dose OXIRI (LD-OXIRI) for metastatic pancreatic cancer.
Treatment: Low Dose OXIRI (LD-OXIRI) — This is a single-centre, non-randomized, open label phase II trial to be conducted at the National Cancer Centre, Singapore (NCCS). Patients diagnosed with metastatic PDAC will be eligible to enrol. The investigators hypothesize the anticancer activity of low dose OXIRI (LD-OXIRI) regimen comprising of metronomic oxaliplatin (O) and metronomic capecitabine (xeloda; X) in combination with UGT1A1-directed dosing of irinotecan (IRI) to be a tolerable regimen in patients with advanced PDAC and will lead to a favourable response rate. Patients will be prospectively enrolled in two stages - In stage 1, patients will be recruited and evaluated for response and toxicity. In stage 2, more patients will be recruited for further evaluation of response and toxicity.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: palliative chemotherapy
Treatment with palliative chemotherapy or radiotherapy within 4 weeks prior to enrolment into the study
Cannot have received: radiation therapy
Treatment with palliative chemotherapy or radiotherapy within 4 weeks prior to enrolment into the study
Lab requirements
Blood counts
granulocyte count ≥ 1.5 × 10**9/l, platelet count ≥ 100 × 10**9/l
Kidney function
creatinine clearance > 50 ml/min
Liver function
total bilirubin ≤ 1.5 x uln, ast and alt, alp ≤ 3 x uln or < 5 x uln in case of hepatic involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify